13G Filing: 683 Capital Partners and Tracon Pharmaceuticals Inc. (TCON)

This Schedule 13G reflects the beneficial ownership of the Reporting Persons (as defined below) as of September 18, 2017.

Item 1(a).

Name of Issuer:

Tracon Pharmaceuticals, Inc. (“Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

4350 La Jolla Village Drive, Suite 800, San Diego, CA 92122

Item 2(a).

Name of Persons Filing:

The names of the persons filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are:

·	683 Capital Management, LLC,

·	683 Capital Partners, LP and

·	Ari Zweiman.

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The principal business address for each of the Reporting Persons is 3 Columbus Circle, Suite 2205, New York, NY 10019.

Item 2(c).

Citizenship:

683 Capital Management, LLC is a Delaware limited liability company.  683 Capital Partners, LP is a Delaware limited partnership.  Ari Zweiman is a citizen of the United States.

Item 2(d).

Title of Class of Securities:

Common stock, $0.001 par value (the “Common Stock”)

Item 2(e).

CUSIP Number:

89237H100

Item 3.

If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: